{"schema":"sb.node.v1","id":"sb:e/b9ca92968673ef89fff242c6","kind":"entity","label":{"text":"regeneron","locale":"en"},"identity":{"anchor":"label:en:regeneron","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T13:13:12.220585+00:00","snapshot":"deploy 0179e3ac7995bc9e92bae3a80f173732f24a5d75"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":48,"separatePublishers":25,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":12,"of":12,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-08","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.167: about 83% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma","auto"],"activeDays":24,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/b1396dc073b0420bf061c731","kind":"observation","label":"SEC · 2026-10-06 · 8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm"},{"id":"sb:o/db672797e13255b8bd48ab34","kind":"observation","label":"AllSci News · 2026-10-04 · Regeneron’s ubamatamab posts 73% response rate in small LGSOC cohort","url":"https://allsci.com/news/biotech/ubamatamab-lgsoc-shows-early-promise-in-small/"},{"id":"sb:o/56bde937b6f2355ecf8a7caa","kind":"observation","label":"Medical Daily · 2026-10-04 · Experimental Regeneron Antibody Trevogrumab Cut Lean Mass Loss by About 42% in Semaglutide Users Over One Year","url":"https://www.medicaldaily.com/trevogrumab-semaglutide-lean-mass-courage-one-year-479482"},{"id":"sb:o/0566e313c0d683a028bbb5f6","kind":"observation","label":"Endpoints News · 2026-10-03 · Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and more","url":"https://endpoints.news/eli-lillys-best-ever-weight-loss-data-sanofi-regeneron-re-up-for-1b-upfront-and-more/"},{"id":"sb:o/aae8c22208f982202bc21a76","kind":"observation","label":"BioPharma Dive · 2026-10-02 · Sanofi, Regeneron broaden alliance to find their next Dupixent","url":"https://www.biopharmadive.com/news/sanofi-regeneron-alliance-expanded-dupixent-immunology-drugs-development/831894/"},{"id":"sb:o/960c9b42d634ff64d7a702db","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses","url":"https://www.clinicaltrialsarena.com/news/easd-2026-regenerons-muscle-preserver-shows-benefit-at-lower-doses/"},{"id":"sb:o/ab3aa70959f0000668486eae","kind":"observation","label":"Endpoints News · 2026-10-02 · #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy","url":"https://endpoints.news/easd26-regenerons-antibody-helps-patients-regain-muscle-after-stopping-glp-1-therapy/"},{"id":"sb:o/90edec423bc9e614b75cd8a5","kind":"observation","label":"Endpoints News · 2026-10-02 · #EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy","url":"https://endpoints.news/easd26-regeneron-sees-a-future-combining-its-obesity-drug-with-lipid-lowering-therapy/"},{"id":"sb:o/1bb7e1651b3a27edd8ec3373","kind":"observation","label":"Endpoints News · 2026-10-01 · Sanofi builds on immunology alliance with Regeneron for $1B upfront","url":"https://endpoints.news/sanofi-builds-on-immunology-alliance-with-regeneron-for-1b-upfront/"},{"id":"sb:o/b807be493d1ddf778e00eb31","kind":"observation","label":"STAT News · 2026-10-01 · STAT+: Sanofi, Regeneron expand partnership after Dupixent success","url":"https://www.statnews.com/2026/10/01/sanofi-regeneron-agreement-dupixent-antibodies-immunology/?utm_campaign=rss"}],"cursor":"c1.eyJpZCI6InNiOmUvYjljYTkyOTY4NjczZWY4OWZmZjI0MmM2IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDEzOjEzOjEyLjIyMDU4NSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with sanofi (21 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/371222d473d4cc26ff82a2ce"},{"kind":"relation","label":"co-mentioned with fda (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3fcf3e2f9527dce0469bf4e8"},{"kind":"relation","label":"co-mentioned with pfizer (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a29483b79ec4cb3c50eaba35"},{"kind":"relation","label":"co-mentioned with studie (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fb6e952d98d08741aa7921f6"},{"kind":"relation","label":"co-mentioned with amgen (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c221fc98857579f0f4c5c075"},{"kind":"relation","label":"co-mentioned with eli lilly (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b33bcf268530e4f416215da9"},{"kind":"relation","label":"co-mentioned with roche (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e6f213bde9fe5b5dc0abda46"},{"kind":"relation","label":"co-mentioned with abbvie (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4e7bbaaefd446b6f098660ed"},{"kind":"relation","label":"co-mentioned with bristol myers squibb (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b1ae724a0048f48a93fdcc9f"},{"kind":"relation","label":"co-mentioned with novartis (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a6abfa138da6225d393bf744"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/b9ca92968673ef89fff242c6","mcp":"traverse {\"id\":\"sb:e/b9ca92968673ef89fff242c6\"}","page":"/entity/regeneron/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b9ca92968673ef89fff242c6\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b9ca92968673ef89fff242c6\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b9ca92968673ef89fff242c6\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b9ca92968673ef89fff242c6\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}